Logo image of BSGM

BIOSIG TECHNOLOGIES INC (BSGM) Stock Fundamental Analysis

NASDAQ:BSGM - Nasdaq - US09073N3008 - Common Stock - Currency: USD

0.925  +0.1 (+12.13%)

After market: 0.9632 +0.04 (+4.13%)

Fundamental Rating

1

BSGM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of BSGM have multiple concerns. While showing a medium growth rate, BSGM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BSGM has reported negative net income.
In the past year BSGM has reported a negative cash flow from operations.
BSGM had negative earnings in each of the past 5 years.
BSGM had a negative operating cash flow in each of the past 5 years.
BSGM Yearly Net Income VS EBIT VS OCF VS FCFBSGM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

BSGM's Return On Assets of -1589.24% is on the low side compared to the rest of the industry. BSGM is outperformed by 98.94% of its industry peers.
Industry RankSector Rank
ROA -1589.24%
ROE N/A
ROIC N/A
ROA(3y)-828.31%
ROA(5y)-579.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BSGM Yearly ROA, ROE, ROICBSGM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

1.3 Margins

With a decent Gross Margin value of 66.67%, BSGM is doing good in the industry, outperforming 71.28% of the companies in the same industry.
BSGM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BSGM Yearly Profit, Operating, Gross MarginsBSGM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50K -100K -150K

More info and screens

0

2. Health

2.1 Basic Checks

BSGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BSGM has more shares outstanding
Compared to 5 years ago, BSGM has more shares outstanding
BSGM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BSGM Yearly Shares OutstandingBSGM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
BSGM Yearly Total Debt VS Total AssetsBSGM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -271.26, we must say that BSGM is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -271.26, BSGM is doing worse than 95.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -271.26
ROIC/WACCN/A
WACC9.06%
BSGM Yearly LT Debt VS Equity VS FCFBSGM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

BSGM has a Current Ratio of 0.14. This is a bad value and indicates that BSGM is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.14, BSGM is doing worse than 95.74% of the companies in the same industry.
A Quick Ratio of 0.14 indicates that BSGM may have some problems paying its short term obligations.
BSGM has a Quick ratio of 0.14. This is amonst the worse of the industry: BSGM underperforms 95.74% of its industry peers.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.14
BSGM Yearly Current Assets VS Current LiabilitesBSGM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.81% over the past year.
BSGM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -93.71%.
EPS 1Y (TTM)66.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)-93.71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 35.04% on average over the next years. This is a very strong growth
BSGM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 73.21% yearly.
EPS Next Y78.73%
EPS Next 2Y35.04%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y73.21%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

BSGM Yearly Revenue VS EstimatesBSGM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M
BSGM Yearly EPS VS EstimatesBSGM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BSGM. In the last year negative earnings were reported.
Also next year BSGM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BSGM Price Earnings VS Forward Price EarningsBSGM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BSGM Per share dataBSGM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as BSGM's earnings are expected to grow with 35.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.04%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BSGM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOSIG TECHNOLOGIES INC

NASDAQ:BSGM (2/21/2025, 8:04:22 PM)

After market: 0.9632 +0.04 (+4.13%)

0.925

+0.1 (+12.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-14 2024-11-14/dmh
Earnings (Next)04-14 2025-04-14/amc
Inst Owners31.65%
Inst Owner Change13324%
Ins Owners18.09%
Ins Owner Change15.84%
Market Cap15.94M
Analysts82.86
Price Target2.81 (203.78%)
Short Float %3.15%
Short Ratio2.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-41.24%
Min EPS beat(2)-60.78%
Max EPS beat(2)-21.7%
EPS beat(4)1
Avg EPS beat(4)-25.89%
Min EPS beat(4)-62.27%
Max EPS beat(4)41.18%
EPS beat(8)2
Avg EPS beat(8)-14%
EPS beat(12)4
Avg EPS beat(12)-9.9%
EPS beat(16)6
Avg EPS beat(16)-10.81%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)12%
EPS NY rev (3m)12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 590.29
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.6
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0
BVpS-0.24
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1589.24%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.67%
FCFM N/A
ROA(3y)-828.31%
ROA(5y)-579.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.72%
Cap/Sales 522.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.14
Quick Ratio 0.14
Altman-Z -271.26
F-Score1
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)127.53%
Cap/Depr(5y)201.17%
Cap/Sales(3y)404.99%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y78.73%
EPS Next 2Y35.04%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-93.71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y73.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year408.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.8%
OCF growth 3YN/A
OCF growth 5YN/A